Designing new β-lactams: Implications from their targets, resistance factors and synthesizing enzymes

Current Computer-Aided Drug Design

Volumn 7, Issue 1, 2011, Pages 53-80

  Goo, Kian Sim ^a   Sim, Tiow Suan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cephalosporin; Deacetoxycephalosporin C synthase; Penicillin; Penicillin binding proteins; lactam; lactamases

Indexed keywords

AMIDES; ANTIBIOTICS; BACTERIA; BIOCHEMISTRY; BIOSYNTHESIS; CELL MEMBRANES;

CEPHALOSPORIN; DEACETOXYCEPHALOSPORIN C SYNTHASE; PENICILLIN; PENICILLIN- BINDING PROTEINS; RESISTANCE FACTORS; SYNTHASES; TARGET RESISTANCE; Β-LACTAM; Β-LACTAM ANTIBIOTICS; Β-LACTAMASE;

ENZYMES;

AMOXICILLIN; AMPICILLIN; AZLOCILLIN; BAMBERMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BIAPENEM; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFADROXIL; CEFALEXIN; CEFCAPENE PIVOXIL; CEFDITOREN; CEFOTAXIME; CEFTAROLINE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CLOXACILLIN; FROPENEM; METICILLIN; MEZLOCILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PENICILLIN V; PHENETICILLIN; PIPERACILLIN; TEBIPENEM; TICARCILLIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BINDING AFFINITY; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG TARGETING; ENTEROCOCCUS; ENZYME ACTIVE SITE; ENZYME DEGRADATION; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; MUTATION; NEISSERIA GONORRHOEAE; NONHUMAN; PROTEIN DOMAIN; PSEUDOMONAS AERUGINOSA; R FACTOR; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 78951471864     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340911793743538     Document Type: Article

References (295)

1. Demain, A.L.; Elander, R.P. The beta-lactam antibiotics: past,present, and future. Antonie Van Leeuwenhoek, 1999, 75, 5-19.
2. Schneider, T.; Sahl, H.G. An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway. Int. J. Med. Microbiol.,2010, 300, 161-169.
3. Vicente, M.; Hodgson, J.; Massidda, O.; Tonjum, T.; Henriques-Normark, B.; Ron, E.Z. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMSM icrobiol. Rev., 2006, 30, 841-852.
4. Silver, L.L. Multi-targeting by monotherapeutic antibacterials. Nat.Rev. Drug. Discov., 2007, 6, 41-55.
5. Jones, R.N.; Pfaller, M.A. Bacterial resistance: a world wide problem. Diagn. Microbiol. Infect. Dis., 1998, 31, 379-388.
6. French, G.L. Clinical impact and relevance of antibiotic resistance. Adv. Drug Deliv. Rev., 2005, 57, 1514-1527.
7. Wilke, M.S.; Lovering, A.L.; Strynadka, N.C. beta-lactamantibiotic resistance: a current structural perspective. Curr. Opin.Microbiol., 2005, 8, 525-533.
8. Lambert, P.A. Bacterial resistance to antibiotics: modified targetsites. Adv. Drug Deliv. Rev., 2005, 57, 1471-1485.
9. Wright, G.D. Bacterial resistance to antibiotics: enzymaticdegradation and modification. Adv. Drug Deliv. Rev., 2005, 57,1451-1470.
10. Ouzounis, C.A.; Valencia, A. Early bioinformatics: the birth of adiscipline--a personal view. Bioinformatics, 2003, 19, 2176-2190.
11. Simossis, V.; Kleinjung, J.; Heringa, J. An overview of multiplesequence alignment. Curr. Protoc. Bioinformatics, 2003, Chapter3, Unit 3.7.
12. Rajnarayanan, R.V.; Dakshanamurthy, S.; Pattabiraman, N."Teaching old drugs to kill new bugs": structure-based discovery ofanti-SARS drugs. Biochem. Biophys. Res. Commun., 2004, 321,370-378.
13. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem., 2001, 44, 4615-4627.
14. Liljas, A. On the complementarity of methods in structural biology. Acta Crystallogr. D Biol. Crystallogr., 2006, 62, 941-945.
15. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res., 2000, 28, 235-242.
16. Liras, P.; Demain, A.L. Enzymology of beta-lactam compoundswith cephem structure produced by actinomycete. MethodsEnzymol., 2009, 458, 401-429.
17. Goo, K.S.; Chua, C.S.; Sim, T.S. Directed evolution and rationalapproaches to improving Streptomyces clavuligerus deacetoxycephalosporin C synthase for cephalosporin production. J. Ind. Microbiol. Biotechnol., 2009, 36, 619-633.
18. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J.A.; Charlier, P. Thepenicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev., 2008, 32, 234-258.
19. Zapun, A.; Contreras-Martel, C.; Vernet, T. Penicillin-bindingproteins and beta-lactam resistance. FEMS Microbiol. Rev., 2008,32, 361-385.
20. Drawz, S.M.; Bonomo, R.A. Three decades of beta-lactamaseinhibitors. Clin. Microbiol. Rev., 2010, 23, 160-201.
21. Fisher, J.F.; Mobashery, S. Three decades of the class A beta-lactamase acyl-enzyme. Curr. Protein Pept. Sci., 2009, 10, 401-407.
22. Page, M. I.; Badarau, A. The mechanisms of catalysis by metallobeta-lactamases. Bioinorg. Chem. Appl., 2008, 576297.
23. Abraham, E.P.; Newton, G.G. The structure of cephalosporin C.Biochem. J., 1961, 79, 377-393.
24. Abraham, E. P. A glimpse of the early history of the cephalosporins. Rev. Infect. Dis., 1979, 1, 99-105.
25. Liras, P. Biosynthesis and molecular genetics of cephamycins -Cephamycins produced by Actinomycetes. Antonie VanLeeuwenhoek, 1999, 75, 109-124.
26. Brakhage, A.A.; Al-Abdallah, Q.; Tuncher, A.; Sprote, P. Evolution of beta-lactam biosynthesis genes and recruitment oftrans-acting factors. Phytochemistry, 2005, 66, 1200-1210.
27. Queener, S. W. Molecular biology of penicillin and cephalosporinbiosynthesis. Antimicrob. Agents Chemother., 1990, 34, 943-948.
28. Martin, J. F. New aspects of genes and enzymes for beta-lactamantibiotic biosynthesis. Appl. Microbiol. Biotechnol., 1998, 50, 1-15.
29. Kreisberg-Zakarin, R.; Borovok, I.; Yanko, M.; Aharonowitz, Y.; Cohen, G. Recent advances in the structure and function of isopenicillin N synthase. Antonie Van Leeuwenhoek, 1999, 75, 33-39.
30. Barends, T.R.; Yoshida, H.; Dijkstra, B.W. Three-dimensionalstructures of enzymes useful for beta-lactam antibiotic production.Curr. Opin. Biotechnol., 2004, 15, 356-363.
31. Andersson, I.; van Scheltinga, A.C.T.; Valegard, K. Towards newbeta-lactam antibiotics. Cell. Mol. Life Sci., 2001, 58, 1897-1906.
32. Roach, P.L.; Clifton, I.J.; Fulop, V.; Harlos, K.; Barton, G.J.; Hajdu, J.; Andersson, I.; Schofield, C.J.; Baldwin, J.E. Crystal structure of isopenicillin N synthase is the first from a new structural family of enzymes. Nature, 1995, 375, 700-704.
33. Roach, P.L.; Clifton, I.J.; Hensgens, C.M.; Shibata, N.; Schofield, C. J.; Hajdu, J.; Baldwin, J.E. Structure of isopenicillin N synthasecomplexed with substrate and the mechanism of penicillin formation. Nature, 1997, 387, 827-830.
34. Rowe, C.J.; Shorrock, C.P.; Claridge, T.D.; Sutherland, J. D. Analysis of the conversion of delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-alpha-aminobutyrate by active-site mutants ofAspergillus nidulans isopenicillin N synthase. Chem. Biol., 1998, 5,229-239.
35. Howard-Jones, A.R.; Elkins, J.M.; Clifton, I.J.; Roach, P. L.; Adlington, R. M.; Baldwin, J.E.; Rutledge, P. J. Interactions of isopenicillin N synthase with cyclopropyl-containing substrate analogues reveal new mechanistic insight. Biochemistry, 2007, 46,4755-4762.
36. Long, A.J.; Clifton, I.J.; Roach, P.L.; Baldwin, J.E.; Schofield, C.J.; Rutledge, P.J. Structural studies on the reaction of isopenicillin Nsynthase with the substrate analogue delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-alpha-aminobutyrate. Biochem. J., 2003, 372, 687-693.
37. Elkins, J.M.; Rutledge, P.J.; Burzlaff, N.I.; Clifton, I.J.; Adlington, R. M.; Roach, P.L.; Baldwin, J.E. Crystallographic studies on thereaction of isopenicillin N synthase with an unsaturated substrate analogue. Org. Biomol. Chem., 2003, 1, 1455-1460.
38. Barredo, J.L.; van Solingen, P.; Diez, B.; Alvarez, E.; Cantoral, J. M.; Kattevilder, A.; Smaal, E.B.; Groenen, M.A.; Veenstra, A. E.; Martin, J. F. Cloning and characterization of the acyl-coenzyme A:6-aminopenicillanic-acid-acyltransferase gene of Penicillium chrysogenum. Gene, 1989, 83, 291-300.
39. Dotzlaf, J.E.; Yeh, W.K. Copurification and characterization ofdeacetoxycephalosporin C synthetase/hydroxylase from Cephalosporium acremonium. J. Bacteriol., 1987, 169, 1611-1618.
40. Barber, M.S.; Giesecke, U.; Reichert, A.; Minas, W. Industrial enzymatic production of cephalosporin-based beta-lactams. In Molecular Biotechnology of Fungal beta-lactam Antibiotics and Related Peptide Synthetases, 2004, 88, 179-215.
41. Valegard, K.; van Scheltinga, A.C.; Lloyd, M.D.; Hara, T.; Ramaswamy, S.; Perrakis, A.; Thompson, A.; Lee, H.J.; Baldwin, J. E.; Schofield, C.J.; Hajdu, J.; Andersson, I. Structure of acephalosporin synthase. Nature, 1998, 394, 805-809.
42. Chin, H.S.; Sim, J.; Sim, T.S. Mutation of N304 to leucine inStreptomyces clavuligerus deacetoxycephalosporin C synthasecreates an enzyme with increased penicillin analogue conversion. Biochem. Biophys. Res. Commun., 2001, 287, 507-513.
43. Sim, J.; Sim, T.S. Mutational evidence supporting the involvementof tripartite residues His183, Asp185, and His243 in Streptomycesclavuligerus deacetoxycephalosporin C synthase for catalysis. Biosci. Biotechnol. Biochem., 2000, 64, 828-832.
44. Baez-Vasquez, M.A.; Adrio, J.L.; Piret, J.M.; Demain, A.L. Furtherstudies on the bioconversion of penicillin G into deacetoxy cephalosporin G by resting cells of Streptomyces clavuligerus NP-1. Appl. Biochem. Biotechnol., 1999, 81, 145-152.
45. Demain, A.L.; Baez-Vasquez, M.A. Immobilized Streptomyces clavuligerus NP1 cells for biotransformation of penicillin G intodeacetoxycephalosporin G. Appl. Biochem. Biotechnol., 2000, 87,135-140.
46. Gao, Q.; Piret, J.M.; Adrio, J.L.; Demain, A.L. Performance of arecombinant strain of Streptomyces lividans for bioconversion ofpenicillin G to deacetoxycephalosporin G. J. Ind. Microbiol. Biotechnol., 2003, 30, 190-194.
47. Wei, C.L.; Yang, Y.B.; Wang, W.C.; Liu, W.C.; Hsu, J.S.; Tsai, Y. C. Engineering Streptomyces clavuligerus deacetoxycephalos-porin C synthase for optimal ring expansion activity towardpenicillin G. Appl. Environ. Microbiol., 2003, 69, 2306-2312.
48. Shen, Y.Q.; Wolfe, S.; Demain, A.L. Deacetoxycephalosporin Csynthetase - importance of order of cofactor/reactant addition. Enzyme Microb. Technol. 1984, 6, 402-404.
49. Cho, H.; Adrio, J.L.; Luengo, J.M.; Wolfe, S.; Ocran, S.; Hintermann, G.; Piret, J.M.; Demain, A.L. Elucidation ofconditions allowing conversion of penicillin G and other penicillinsto deacetoxycephalosporins by resting cells and extracts of Streptomyces clavuligerus NP1. Proc. Natl. Acad. Sci. USA, 1998,95, 11544-11548.
50. Sim, J.; Sim, T. S. In vitro conversion of penicillin G and ampicillinby recombinant Streptomyces clavuligerus NRRL 3585deacetoxycephalosporin C synthase. Enzyme Microb. Technol.,2001, 29, 240-245.
51. Wei, C.L.; Yang, Y.B.; Deng, C.H.; Liaw, S.H.; Tsai, Y. C. Directed evolution of Streptomyces clavuligerus deacetoxy-cephalosporin C synthase for enhancement of penicillin Gexpansion. FEBS J., 2008, 275, 180-180.
52. Chin, H.S.; Sim, T.S. C-terminus modification of Streptomycesclavuligerus deacetoxycephalosporin C synthase improves catalysis with an expanded substrate specificity. Biochem. Biophys. Res. Commun., 2002, 295, 55-61.
53. Chin, H.S.; Sim, J.; Seah, K.I.; Sim, T.S. DeacetoxycephalosporinC synthase isozymes exhibit diverse catalytic activity and substratespecificity. FEMS Microbiol. Lett., 2003, 218 (2), 251-257.
54. Valegard, K.; van Scheltinga, A.C.T.; Dubus, A.; Ranghino, G.; Oster, L.M.; Hajdu, J.; Andersson, I. The structural basis ofcephalosporin formation in a mononuclear ferrous enzyme. Nat.Struct. Mol. Biol., 2004, 11, 95-101.
55. Chin, H.S.; Goo, K.S.; Sim, T.S. A complete library of amino acidalterations at N304 in Streptomyces clavuligerusdeacetoxycephalosporin C synthase elucidates the basis forenhanced penicillin analogue conversion. Appl. Environ.Microbiol., 2004, 70, 607-609.
56. Goo, K.S.; Chua, C.S.; Sim, T.S. A complete library of amino acidalterations at R306 in Streptomyces clavuligerusdeacetoxycephalosporin C synthase demonstrates its structural rolein the ring-expansion activity. Proteins, 2008, 70, 739-747.
57. Wei, C.L.; Yang, Y.B.; Deng, C.H.; Liu, W.C.; Hsu, J.S.; Lin, Y. C.; Liaw, S.H.; Tsai, Y.C. Directed evolution of Streptomycesclavuligerus deacetoxycephalosporin C synthase for enhancementof penicillin G expansion. Appl. Environ. Microbiol., 2005, 71,8873-8880.
58. Goo, K.S.; Chua, C.S.; Sim, T.S. Relevant double mutations inbioengineered Streptomyces clavuligerus deacetoxycephalosporinC synthase result in higher binding specificities which improvepenicillin bioconversion. Appl. Environ. Microbiol., 2008, 74,1167-1175.
59. Velasco, J.; Adrio, J.L.; Moreno, M.A.; Diez, B.; Soler, G.; Barredo, J.L. Environmentally safe production of 7-aminodeacetoxycephalosporanic acid (7-ADCA) usingrecombinant strains of Acremonium chrysogenum. Nat.Biotechnol., 2000, 18, 857-861.
60. Wright, A.J. The penicillins. Mayo Clin. Proc., 1999, 74, 290-307.
61. Chain, E. Thirty years of penicillin therapy. J. R. Coll. PhysiciansLond., 1972, 6, 103-131.
62. Kirby, W.M. Extraction of a highly potent penicillin inactivatorfrom penicillin resistant staphylococci. Science, 1944, 99, 452-453.
63. Rolinson, G.N.; Geddes, A.M. The 50th anniversary of thediscovery of 6-aminopenicillanic acid (6-APA). Int. J. Antimicrob.Agents, 2007, 29, 3-8.
64. Rolinson, G.N. Forty years of beta-lactam research. J. Antimicrob.Chemother., 1998, 41, 589-603.
65. Appelbaum, P. C. MRSA-the tip of the iceberg. Clin. Microbiol.Infect., 2006, 12(Suppl. 2), 3-10.
66. Llarrull, L.I.; Fisher, J.F.; Mobashery, S. Molecular basis andphenotype of methicillin resistance in Staphylococcus aureus andinsights into new beta-lactams that meet the challenge. Antimicrob.Agents Chemother., 2009, 53, 4051-4063.
67. Ubukata, K.; Yamashita, N.; Konno, M. Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci. Antimicrob. Agents Chemother., 1985, 27, 851-857.
68. Matsuhashi, M.; Song, M.D.; Ishino, F.; Wachi, M.; Doi, M.; Inoue, M.; Ubukata, K.; Yamashita, N.; Konno, M. Molecularcloning of the gene of a penicillin-binding protein supposed tocause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J. Bacteriol., 1986, 167, 975-980.
69. Ubukata, K.; Nonoguchi, R.; Matsuhashi, M.; Konno, M. Expression and inducibility in Staphylococcus aureus of the mecAgene, which encodes a methicillin-resistant S. aureus-specificpenicillin-binding protein. J. Bacteriol., 1989, 171, 2882-2885.
70. Miller, L.A.; Ratnam, K.; Payne, D.J. beta-lactamase-inhibitorcombinations in the 21st century: current agents and newdevelopments. Curr. Opin. Pharmacol., 2001, 1, 451-458.
71. Strateva, T.; Yordanov, D. Pseudomonas aeruginosa - aphenomenon of bacterial resistance. J. Med. Microbiol., 2009, 58,1133-1148.
72. Mesaros, N.; Nordmann, P.; Plesiat, P.; Roussel-Delvallez, M.; VanEldere, J.; Glupczynski, Y.; Van Laethem, Y.; Jacobs, F.; Lebecque, P.; Malfroot, A.; Tulkens, P.M.; Van Bambeke, F. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect., 2007, 13, 560-578.
73. Bush, L.M.; Johnson, C.C. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect. Dis. Clin. North Am.,2000, 14, 409-433.
74. Tan, J.S.; File, T.M., Jr. Antipseudomonal penicillins. Med. Clin.North Am., 1995, 79, 679-693.
75. Hamilton-Miller, J.M. Development of the semi-syntheticpenicillins and cephalosporins. Int. J. Antimicrob. Agents, 2008, 31,189-192.
76. st ed.; Pergamon Press:Oxford; New York, 1990.
77. Hamilton-Miller, J.M. Sir Edward Abraham's contribution to thedevelopment of the cephalosporins: a reassessment. Int. J.Antimicrob. Agents, 2000, 15, 179-184.
78. Elander, R. P. Industrial production of beta-lactam antibiotics. Appl. Microbiol. Biotechnol., 2003, 61, 385-392.
79. Marshall, W.F.; Blair, J.E. The cephalosporins. Mayo Clin. Proc.,1999, 74, 187-195.
80. Kanehisa, M.; Goto, S.; Hattori, M.; Aoki-Kinoshita, K.F.; Itoh, M.; Kawashima, S.; Katayama, T.; Araki, M.; Hirakawa, M. Fromgenomics to chemical genomics: new developments in KEGG. Nucleic Acids Res., 2006, 34, D354-357.
81. Projan, S.J. Why is big Pharma getting out of antibacterial drugdiscovery? Curr. Opin. Microbiol., 2003, 6, 427-430.
82. Deresinski, S.C. Ceftobiprole: breaking therapeutic dogmas of thebeta-lactam class. Diagn. Microbiol. Infect. Dis., 2008, 61, 82-85.
83. Villegas-Estrada, A.; Lee, M.; Hesek, D.; Vakulenko, S. B.; Mobashery, S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a bytwo anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc., 2008,130, 9212-9213.
84. Zhanel, G.G.; Lam, A.; Schweizer, F.; Thomson, K.; Walkty, A.; Rubinstein, E.; Gin, A.S.; Hoban, D.J.; Noreddin, A.M.; Karlowsky, J.A. Ceftobiprole: a review of a broad-spectrum andanti-MRSA cephalosporin. Am. J. Clin. Dermatol., 2008, 9, 245-254.
85. Barbour, A.; Schmidt, S.; Rand, K.H.; Derendorf, H. Ceftobiprole:a novel cephalosporin with activity against Gram-positive andGram-negative pathogens, including methicillin-resistantStaphylococcus aureus (MRSA). Int. J. Antimicrob. Agents, 2009,34, 1-7.
86. Fuda, C.; Hesek, D.; Lee, M.; Heilmayer, W.; Novak, R.; Vakulenko, S.B.; Mobashery, S. Mechanistic basis for the action ofnew cephalosporin antibiotics effective against methicillin-and vancomycin-resistant Staphylococcus aureus. J. Biol. Chem., 2006,281, 10035-10041.
87. Murano, K.; Yamanaka, T.; Toda, A.; Ohki, H.; Okuda, S.; Kawabata, K.; Hatano, K.; Takeda, S.; Akamatsu, H.; Itoh, K.; Misumi, K.; Inoue, S.; Takagi, T. Structural requirements for thestability of novel cephalosporins to AmpC beta-lactamase based on3D-structure. Bioorg. Med. Chem., 2008, 16, 2261-2275.
88. Toda, A.; Ohki, H.; Yamanaka, T.; Murano, K.; Okuda, S.; Kawabata, K.; Hatano, K.; Matsuda, K.; Misumi, K.; Itoh, K.; Satoh, K.; Inoue, S. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg. Med. Chem. Lett., 2008, 18, 4849-4852.
89. Livermore, D. M.; Mushtaq, S.; Ge, Y.; Warner, M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonasaeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents, 2009, 34, 402-406.
90. Giske, C.G.; Ge, J.; Nordmann, P. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa. J. Antimicrob.Chemother., 2009, 64, 430-431.
91. Zamorano, L.; Juan, C.; Fernandez-Olmos, A.; Ge, Y.; Canton, R.; Oliver, A. Activity of the new cephalosporin CXA-101(FR264205) against Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. Clin. Microbiol. Infect.2010. Epub on 16 Feb.
92. Popham, D.L.; Setlow, P. Phenotypes of Bacillus subtilis mutantslacking multiple class A high-molecular-weight penicillin-bindingproteins. J. Bacteriol., 1996, 178, 2079-2085.
93. Popham, D.L.; Young, K.D. Role of penicillin-binding proteins inbacterial cell morphogenesis. Curr. Opin. Microbiol., 2003, 6, 594-599.
94. Popham, D.L.; Setlow, P. Cloning, nucleotide sequence, andmutagenesis of the Bacillus subtilis ponA operon, which codes forpenicillin-binding protein (PBP) 1 and a PBP-related factor. J.Bacteriol., 1995, 177, 326-335.
95. McPherson, D.C.; Popham, D.L. Peptidoglycan synthesis in theabsence of class A penicillin-binding proteins in Bacillus subtilis.J. Bacteriol., 2003, 185, 1423-1431.
96. Denome, S.A.; Elf, P.K.; Henderson, T.A.; Nelson, D.E.; Young, K. D. Escherichia coli mutants lacking all possible combinations ofeight penicillin binding proteins: viability, characteristics, andimplications for peptidoglycan synthesis. J. Bacteriol., 1999, 181,3981-3993.
97. Macheboeuf, P.; Contreras-Martel, C.; Job, V.; Dideberg, O.; Dessen, A. Penicillin binding proteins: key players in bacterial cellcycle and drug resistance processes. FEMS Microbiol. Rev., 2006,30, 673-691.
98. Den Blaauwen, T.; Aarsman, M.E.; Vischer, N.O.; Nanninga, N.Penicillin-binding protein PBP2 of Escherichia coli localizespreferentially in the lateral wall and at mid-cell in comparison withthe old cell pole. Mol. Microbiol., 2003, 47, 539-547.
99. Spratt, B.G.; Pardee, A.B. Penicillin-binding proteins and cellshape in E. coli. Nature, 1975, 254, 516-517.
100. Di Lallo, G.; Fagioli, M.; Barionovi, D.; Ghelardini, P.; Paolozzi, L. Use of a two-hybrid assay to study the assembly of a complexmulticomponent protein machinery: bacterial septo some differentiation. Microbiology, 2003, 149, 3353-3359.
101. Karimova, G.; Dautin, N.; Ladant, D. Interaction network among Escherichia coli membrane proteins involved in cell division asrevealed by bacterial two-hybrid analysis. J. Bacteriol., 2005, 187,2233-2243.
102. Spratt, B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc. Natl. Acad. Sci. USA, 1975, 72, 2999-3003.
103. Carballido-Lopez, R.; Formstone, A. Shape determination inBacillus subtilis. Curr. Opin. Microbiol., 2007, 10, 611-616.
104. Wei, Y.; Havasy, T.; McPherson, D.C.; Popham, D. L. Rod shapedetermination by the Bacillus subtilis class B penicillin-bindingproteins encoded by pbpA and pbpH. J. Bacteriol., 2003, 185,4717-4726.
105. Morlot, C.; Noirclerc-Savoye, M.; Zapun, A.; Dideberg, O.; Vernet, T. The D, D-carboxypeptidase PBP3 organizes the divisionprocess of Streptococcus pneumoniae. Mol. Microbiol., 2004, 51,1641-1648.
106. Vollmer, W.; Holtje, J.V. The architecture of the murein(peptidoglycan) in gram-negative bacteria: vertical scaffold orhorizontal layer(s)? J. Bacteriol., 2004, 186, 5978-5987.
107. Vollmer, W.; Joris, B.; Charlier, P.; Foster, S. Bacterialpeptidoglycan (murein) hydrolases. FEMS Microbiol. Rev., 2008,32, 259-286.
108. Spratt, B.G.; Strominger, J.L. Identification of the major penicillin-binding proteins of Escherichia coli as D-alanine carboxypeptidase IA. J. Bacteriol., 1976, 127, 660-663.
109. Zapun, A.; Vernet, T.; Pinho, M.G. The different shapes of cocci. FEMS Microbiol. Rev., 2008, 32, 345-360.
110. Strominger, J.L.; Tipper, D.J. Bacterial cell wall synthesis andstructure in relation to the mechanism of action of penicillins andother antibacterial agents. Am. J. Med., 1965, 39, 708-721.
111. Chen, Y.; Zhang, W.; Shi, Q.; Hesek, D.; Lee, M.; Mobashery, S.; Shoichet, B.K. Crystal structures of penicillin-binding protein 6from Escherichia coli. J. Am. Chem. Soc., 2009, 131, 14345-14354.
112. Frere, J.M.; Ghuysen, J.M.; Iwatsubo, M. Kinetics of interactionbetween the exocellular DD-carboxypeptidase-transpeptidase fromStreptomyces R61 and beta-lactam antibiotics. A choice of models. Eur. J. Biochem., 1975, 57, 343-351.
113. Massova, I.; Mobashery, S. Kinship and diversification of bacterialpenicillin-binding proteins and beta-lactamases. Antimicrob. AgentsChemother., 1998, 42, 1-17.
114. Contreras-Martel, C.; Dahout-Gonzalez, C.; Martins Ados, S.; Kotnik, M.; Dessen, A. PBP active site flexibility as the keymechanism for beta-lactam resistance in pneumococci. J. Mol.Biol., 2009, 387, 899-909.
115. Sauvage, E.; Powell, A.J.; Heilemann, J.; Josephine, H.R.; Charlier, P.; Davies, C.; Pratt, R.F. Crystal structures of complexes ofbacterial DD-peptidases with peptidoglycan-mimetic ligands: the substrate specificity puzzle. J. Mol. Biol., 2008, 381, 383-393.
116. Zhang, W.; Shi, Q.; Meroueh, S.O.; Vakulenko, S.B.; Mobashery, S. Catalytic mechanism of penicillin-binding protein 5 ofEscherichia coli. Biochemistry, 2007, 46, 10113-10121.
117. Oliva, M.; Dideberg, O.; Field, M.J., Understanding the acylationmechanisms of active-site serine penicillin-recognizing proteins: amolecular dynamics simulation study. Proteins, 2003, 53, 88-100.
118. Massova, I.; Kollman, P.A. pKa, MM, and QM studies ofmechanisms of beta-lactamases and penicillin-binding proteins:acylation step. J. Comput. Chem., 2002, 23, 1559-1576.
119. Gordon, E.; Mouz, N.; Duee, E.; Dideberg, O. The crystal structureof the penicillin-binding protein 2x from Streptococcuspneumoniae and its acyl-enzyme form: implication in drugresistance. J. Mol. Biol., 2000, 299, 477-485.
120. Morlot, C.; Pernot, L.; Le Gouellec, A.; Di Guilmi, A.M.; Vernet, T.; Dideberg, O.; Dessen, A. Crystal structure of a peptidoglycansynthesis regulatory factor (PBP3) from Streptococcuspneumoniae. J. Biol. Chem., 2005, 280, 15984-15991.
121. Chesnel, L.; Zapun, A.; Mouz, N.; Dideberg, O.; Vernet, T. Increase of the deacylation rate of PBP2x from Streptococcuspneumoniae by single point mutations mimicking the class A beta-lactamases. Eur. J. Biochem., 2002, 269, 1678-1683.
122. Nicholas, R.A.; Krings, S.; Tomberg, J.; Nicola, G.; Davies, C. Crystal structure of wild-type penicillin-binding protein 5 fromEscherichia coli: implications for deacylation of the acyl-enzymecomplex. J. Biol. Chem., 2003, 278, 52826-52833.
123. Davies, C.; White, S.W.; Nicholas, R.A. Crystal structure of adeacylation-defective mutant of penicillin-binding protein 5 at 2.3-A resolution. J. Biol. Chem., 2001, 276, 616-623.
124. Nicola, G.; Peddi, S.; Stefanova, M.; Nicholas, R.A.; Gutheil, W. G.; Davies, C. Crystal structure of Escherichia coli penicillin-binding protein 5 bound to a tripeptide boronic acid inhibitor: a rolefor Ser-110 in deacylation. Biochemistry, 2005, 44, 8207-8217.
125. Sauvage, E.; Duez, C.; Herman, R.; Kerff, F.; Petrella, S.; Anderson, J.W.; Adediran, S.A.; Pratt, R.F.; Frere, J.M.; Charlier, P. Crystal structure of the Bacillus subtilis penicillin-binding protein 4a, and its complex with a peptidoglycan mimetic peptide.J. Mol. Biol., 2007, 371, 528-539.
126. Fuda, C.; Suvorov, M.; Vakulenko, S.B.; Mobashery, S. The basisfor resistance to beta-lactam antibiotics by penicillin-bindingprotein 2a of methicillin-resistant Staphylococcus aureus. J. Biol.Chem., 2004, 279, 40802-40806.
127. Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguchi, A.; Aoki, K.; Nagai, Y.; Lian, J.; Ito, T.; Kanamori, M.; Matsumaru, H.; Maruyama, A.; Murakami, H.; Hosoyama, A.; Mizutani-Ui, Y.; Takahashi, N.K.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K.; Hirakawa, H.; Kuhara, S.; Goto, S.; Yabuzaki, J.; Kanehisa, M.; Yamashita, A.; Oshima, K.; Furuya, K.; Yoshino, C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K. Whole genome sequencing ofmeticillin-resistant Staphylococcus aureus. Lancet, 2001, 357, 1225-1240.
128. Hiramatsu, K.; Cui, L.; Kuroda, M.; Ito, T. The emergence andevolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol., 2001, 9, 486-493.
129. Zhou, Y.; Antignac, A.; Wu, S.W.; Tomasz, A. Penicillin-bindingproteins and cell wall composition in beta-lactam-sensitive and -resistant strains of Staphylococcus sciuri. J. Bacteriol., 2008, 190,508-514.
130. Fuda, C.; Suvorov, M.; Shi, Q.; Hesek, D.; Lee, M.; Mobashery, S. Shared functional attributes between the mecA gene product ofStaphylococcus sciuri and penicillin-binding protein 2a ofmethicillin-resistant Staphylococcus aureus. Biochemistry, 2007,46, 8050-8057.
131. Lim, D.; Strynadka, N.C. Structural basis for the beta lactamresistance of PBP2a from methicillin-resistant Staphylococcusaureus. Nat. Struct. Biol., 2002, 9, 870-876.
132. Lu, W.P.; Kincaid, E.; Sun, Y.; Bauer, M.D. Kinetics of beta-lactam interactions with penicillin-susceptible and -resistantpenicillin-binding protein 2x proteins from Streptococcuspneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. J. Biol. Chem., 2001, 276, 31494-31501.
133. Lu, W.P.; Sun, Y.; Bauer, M.D.; Paule, S.; Koenigs, P.M.; Kraft, W. G. Penicillin-binding protein 2a from methicillin-resistantStaphylococcus aureus: kinetic characterization of its interactionswith beta-lactams using electrospray mass spectrometry. Biochemistry, 1999, 38, 6537-6546.
134. Kishida, H.; Unzai, S.; Roper, D.I.; Lloyd, A.; Park, S.Y.; Tame, J. R. Crystal structure of penicillin binding protein 4 (dacB) fromEscherichia coli, both in the native form and covalently linked tovarious antibiotics. Biochemistry, 2006, 45, 783-792.
135. Grebe, T.; Hakenbeck, R. Penicillin-binding proteins 2b and 2x ofStreptococcus pneumoniae are primary resistance determinants fordifferent classes of beta-lactam antibiotics. Antimicrob. AgentsChemother., 1996, 40, 829-834.
136. Smith, A.M.; Klugman, K.P. Alterations in PBP 1A essential-forhigh-level penicillin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 1998, 42, 1329-1333.
137. Contreras-Martel, C.; Job, V.; Di Guilmi, A.M.; Vernet, T.; Dideberg, O.; Dessen, A. Crystal structure of penicillin-bindingprotein 1a (PBP1a) reveals a mutational hotspot implicated in beta-lactam resistance in Streptococcus pneumoniae. J. Mol. Biol., 2006,355, 684-696.
138. Pares, S.; Mouz, N.; Petillot, Y.; Hakenbeck, R.; Dideberg, O. X-ray structure of Streptococcus pneumoniae PBP2x, a primarypenicillin target enzyme. Nat. Struct. Biol., 1996, 3, 284-289.
139. Dessen, A.; Mouz, N.; Gordon, E.; Hopkins, J.; Dideberg, O. Crystal structure of PBP2x from a highly penicillin-resistantStreptococcus pneumoniae clinical isolate: a mosaic frameworkcontaining 83 mutations. J. Biol. Chem., 2001, 276, 45106-45112.
140. Mouz, N.; Gordon, E.; Di Guilmi, A.M.; Petit, I.; Petillot, Y.; Dupont, Y.; Hakenbeck, R.; Vernet, T.; Dideberg, O. Identificationof a structural determinant for resistance to beta-lactam antibioticsin Gram-positive bacteria. Proc. Natl. Acad. Sci. USA, 1998, 95,13403-13406.
141. Garcia-Bustos, J.F.; Chait, B.T.; Tomasz, A. Altered peptidoglycanstructure in a pneumococcal transformant resistant to penicillin. J.Bacteriol., 1988, 170, 2143-2147.
142. Severin, A.; Tomasz, A. Naturally occurring peptidoglycan variantsof Streptococcus pneumoniae. J. Bacteriol., 1996, 178, 168-174.
143. Garcia-Bustos, J.; Tomasz, A. A biological price of antibioticresistance: major changes in the peptidoglycan structure ofpenicillin-resistant pneumococci. Proc. Natl. Acad. Sci. USA, 1990,87, 5415-5419.
144. Carapito, R.; Chesnel, L.; Vernet, T.; Zapun, A. Pneumococcalbeta-lactam resistance due to a conformational change in penicillin-binding protein 2x. J. Biol. Chem., 2006, 281, 1771-1777.
145. Pagliero, E.; Chesnel, L.; Hopkins, J.; Croize, J.; Dideberg, O.; Vernet, T.; Di Guilmi, A.M. Biochemical characterization ofStreptococcus pneumoniae penicillin-binding protein 2b and itsimplication in beta-lactam resistance. Antimicrob. Agents Chemother., 2004, 48, 1848-1855.
146. Nagai, K.; Davies, T.A.; Jacobs, M.R.; Appelbaum, P.C. Effects ofamino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b,and 2x on PBP affinities of penicillin, ampicillin, amoxicillin,cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinicalisolates of penicillin-susceptible, -intermediate, and -resistantpneumococci. Antimicrob. Agents Chemother., 2002, 46, 1273-1280.
147. Navratna, V.; Nadig, S.; Sood, V.; Prasad, K.; Arakere, G.; Gopal,B. Molecular basis for the role of Staphylococcus aureus penicillinbinding protein 4 in antimicrobial resistance. J. Bacteriol., 2010,192, 134-144.
148. Henze, U.U.; Berger-Bachi, B. Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance. Antimicrob.Agents Chemother., 1995, 39, 2415-2422.
149. Sarkar, S.K.; Chowdhury, C.; Ghosh, A.S. Deletion of penicillin-binding protein 5 (PBP5) sensitises Escherichia coli cells to beta-lactam agents. Int. J. Antimicrob. Agents, 2010, 35, 244-249.
150. Guillaume, G.; Vanhove, M.; Lamotte-Brasseur, J.; Ledent, P.; Jamin, M.; Joris, B.; Frere, J.M. Site-directed mutagenesis ofglutamate 166 in two beta-lactamases. Kinetic and molecular modeling studies. J. Biol. Chem., 1997, 272, 5438-5444.
151. Moya, B.; Dotsch, A.; Juan, C.; Blazquez, J.; Zamorano, L.; Haussler, S.; Oliver, A. beta-lactam resistance response triggeredby inactivation of a non-essential penicillin-binding protein. PLoS Pathog., 2009, 5, e1000353.
152. Ambler, R. P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1980, 289, 321-331.
153. Bush, K. Characterization of beta-lactamases. Antimicrob. AgentsChemother., 1989, 33, 259-263.
154. Bush, K.; Jacoby, G.A.; Medeiros, A. A. A functional classificationscheme for beta-lactamases and its correlation with molecularstructure. Antimicrob. Agents Chemother., 1995, 39, 1211-1233.
155. Jaurin, B.; Grundstrom, T. ampC cephalosporinase of Escherichiacoli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. Proc. Natl. Acad. Sci. USA,1981, 78, 4897-4901.
156. Huovinen, P.; Huovinen, S.; Jacoby, G.A. Sequence of PSE-2 beta-lactamase. Antimicrob. Agents Chemother., 1988, 32, 134-136.
157. Petrosino, J.; Cantu, C. 3rd; Palzkill, T. beta-lactamases: proteinevolution in real time. Trends Microbiol., 1998, 6, 323-327.
158. Gniadkowski, M. Evolution of extended-spectrum beta-lactamasesby mutation. Clin. Microbiol. Infect., 2008, 14(Suppl. 1), 11-32.
159. Bonomo, R.A.; Rice, L.B. Inhibitor resistant class A beta-lactamases. Front. Biosci., 1999, 4, e34-41.
160. Mendonca, N.; Manageiro, V.; Robin, F.; Salgado, M.J.; Ferreira, E.; Canica, M.; Bonnet, R. The Lys234Arg substitution in theenzyme SHV-72 is a determinant for resistance to clavulanic acidinhibition. Antimicrob. Agents Chemother., 2008, 52, 1806-1811.
161. Jacoby, G.A. AmpC beta-lactamases. Clin. Microbiol. Rev., 2009,22, 161-182.
162. Hanson, N.D.; Sanders, C.C. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr. Pharm.Des., 1999, 5, 881-894.
163. Bennett, P.M.; Chopra, I. Molecular basis of beta-lactamaseinduction in bacteria. Antimicrob. Agents Chemother., 1993, 37,153-158.
164. Korfmann, G.; Sanders, C.C. ampG is essential for high-levelexpression of AmpC beta-lactamase in Enterobacter cloacae. Antimicrob. Agents Chemother., 1989, 33, 1946-1951.
165. Schmidtke, A.J.; Hanson, N.D. Model system to evaluate the effectof ampD mutations on AmpC-mediated beta-lactam resistance. Antimicrob. Agents Chemother., 2006, 50, 2030-2037.
166. Kaneko, K.; Okamoto, R.; Nakano, R.; Kawakami, S.; Inoue, M. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae. J. Clin.Microbiol., 2005, 43, 2955-2958.
167. Kuga, A.; Okamoto, R.; Inoue, M. ampR gene mutations thatgreatly increase class C beta-lactamase activity in Enterobactercloacae. Antimicrob. Agents Chemother., 2000, 44, 561-567.
168. Nordmann, P.; Poirel, L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect., 2002, 8, 321-331.
169. Bush, K.; Jacoby, G.A. Updated functional classification of beta-lactamases. Antimicrob. Agents Chemother., 2010, 54, 969-976.
170. Paetzel, M.; Danel, F.; de Castro, L.; Mosimann, S.C.; Page, M. G.; Strynadka, N.C. Crystal structure of the class D beta-lactamaseOXA-10. Nat. Struct. Biol., 2000, 7, 918-925.
171. Walsh, T.R.; Toleman, M.A.; Poirel, L.; Nordmann, P. Metallo-beta-lactamases: the quiet before the storm? Clin. Microbiol. Rev.,2005, 18, 306-325.
172. Crowder, M.W.; Spencer, J.; Vila, A.J. Metallo-beta-lactamases:novel weaponry for antibiotic resistance in bacteria. Acc. Chem.Res., 2006, 39, 721-728.
173. Garau, G.; Garcia-Saez, I.; Bebrone, C.; Anne, C.; Mercuri, P.; Galleni, M.; Frere, J.M.; Dideberg, O. Update of the standardnumbering scheme for class B beta-lactamases. Antimicrob. Agents Chemother., 2004, 48, 2347-2349.
174. Galleni, M.; Lamotte-Brasseur, J.; Rossolini, G.M.; Spencer, J.; Dideberg, O.; Frere, J.M. Standard numbering scheme for class Bbeta-lactamases. Antimicrob. Agents Chemother., 2001, 45, 660-663.
175. Kaminskaia, N.V.; Spingler, B.; Lippard, S.J. Intermediate in beta-lactam hydrolysis catalyzed by a dinuclear zinc(II) complex:relevance to the mechanism of metallo-beta-lactamase. J. Am.Chem. Soc., 2001, 123, 6555-6563.
176. Toney, J.H.; Hammond, G.G.; Fitzgerald, P.M.; Sharma, N.; Balkovec, J.M.; Rouen, G.P.; Olson, S.H.; Hammond, M.L.; Greenlee, M.L.; Gao, Y.D. Succinic acids as potent inhibitors ofplasmid-borne IMP-1 metallo-beta-lactamase. J. Biol. Chem., 2001,276, 31913-31918.
177. Rasia, R.M.; Vila, A.J. Structural determinants of substrate bindingto Bacillus cereus metallo-beta-lactamase. J. Biol. Chem., 2004,279, 26046-26051.
178. Ambler, R.P.; Coulson, A.F.; Frere, J.M.; Ghuysen, J.M.; Joris, B.; Forsman, M.; Levesque, R.C.; Tiraby, G.; Waley, S.G. A standardnumbering scheme for the class A beta-lactamases. Biochem. J.,1991, 276, 269-270.
179. Matagne, A.; Lamotte-Brasseur, J.; Frere, J.M. Catalytic propertiesof class A beta-lactamases: efficiency and diversity. Biochem. J.,1998, 330, 581-598.
180. Herzberg, O.; Moult, J. Bacterial resistance to beta-lactamantibiotics: crystal structure of beta-lactamase from Staphylococcusaureus PC1 at 2.5 A resolution. Science, 1987, 236, 694-701.
181. Knox, J.R.; Moews, P.C.; Frere, J.M. Molecular evolution ofbacterial beta-lactam resistance. Chem. Biol., 1996, 3, 937-947.
182. Lobkovsky, E.; Moews, P.C.; Liu, H.; Zhao, H.; Frere, J.M.; Knox, J. R. Evolution of an enzyme activity: crystallographic structure at2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class Apenicillinase. Proc. Natl. Acad. Sci. USA, 1993, 90, 11257-11261.
183. Dubus, A.; Ledent, P.; Lamotte-Brasseur, J.; Frere, J.M. The roles of residues Tyr150, Glu272, and His314 in class C beta-lactamases.Proteins, 1996, 25, 473-485.
184. Oefner, C.; D'Arcy, A.; Daly, J.J.; Gubernator, K.; Charnas, R. L.; Heinze, I.; Hubschwerlen, C.; Winkler, F.K. Refined crystalstructure of beta-lactamase from Citrobacter freundii indicates amechanism for beta-lactam hydrolysis. Nature, 1990, 343, 284-288.
185. Chen, Y.; Minasov, G.; Roth, T.A.; Prati, F.; Shoichet, B.K. Thedeacylation mechanism of AmpC beta-lactamase at ultrahighresolution. J. Am. Chem. Soc., 2006, 128, 2970-2976.
186. Chen, Y.; McReynolds, A.; Shoichet, B.K. Re-examining the roleof Lys67 in class C beta-lactamase catalysis. Protein Sci., 2009, 18,662-669.
187. Docquier, J.D.; Calderone, V.; De Luca, F.; Benvenuti, M.; Giuliani, F.; Bellucci, L.; Tafi, A.; Nordmann, P.; Botta, M.; Rossolini, G.M.; Mangani, S. Crystal structure of the OXA-48beta-lactamase reveals mechanistic diversity among class Dcarbapenemases. Chem. Biol., 2009, 16, 540-547.
188. Maveyraud, L.; Golemi, D.; Kotra, L.P.; Tranier, S.; Vakulenko, S.; Mobashery, S.; Samama, J.P. Insights into class D beta-lactamasesare revealed by the crystal structure of the OXA10 enzyme fromPseudomonas aeruginosa. Structure, 2000, 8, 1289-1298.
189. Sun, T.; Nukaga, M.; Mayama, K.; Braswell, E.H.; Knox, J. R.Comparison of beta-lactamases of classes A and D: 1.5-Acrystallographic structure of the class D OXA-1 oxacillinase. Protein Sci., 2003, 12, 82-91.
190. Baurin, S.; Vercheval, L.; Bouillenne, F.; Falzone, C.; Brans, A.; Jacquamet, L.; Ferrer, J.L.; Sauvage, E.; Dehareng, D.; Frere, J.M.; Charlier, P.; Galleni, M.; Kerff, F. Critical role of tryptophan 154for the activity and stability of class D beta-lactamases. Biochemistry, 2009, 48, 11252-11263.
191. Remy, I.; Ghaddar, G.; Michnick, S.W., Using the beta-lactamaseprotein-fragment complementation assay to probe dynamic protein-protein interactions. Nat. Protoc., 2007, 2, 2302-2306.
192. Shivange, A.V.; Marienhagen, J.; Mundhada, H.; Schenk, A.; Schwaneberg, U. Advances in generating functional diversity for directed protein evolution. Curr. Opin. Chem. Biol., 2009, 13, 19-25.
193. Bershtein, S.; Tawfik, D.S. Advances in laboratory evolution ofenzymes. Curr. Opin. Chem. Biol., 2008, 12, 151-158.
194. Park, H.S.; Nam, S.H.; Lee, J.K.; Yoon, C.N.; Mannervik, B.; Benkovic, S.J.; Kim, H.S. Design and evolution of new catalyticactivity with an existing protein scaffold. Science, 2006, 311, 535-538.
195. De Wals, P.Y.; Doucet, N.; Pelletier, J.N. High tolerance tosimultaneous active-site mutations in TEM-1 beta-lactamase:Distinct mutational paths provide more generalized beta-lactamrecognition. Protein Sci., 2009, 18, 147-160.
196. Le Turnier, S.; Nordmann, P.; Eb, F.; Mammeri, H. Potentialevolution of hydrolysis spectrum for AmpC beta-lactamase ofEscherichia coli. J. Antimicrob. Chemother., 2009, 63, 216-218.
197. Majiduddin, F.K.; Palzkill, T. Amino acid residues that contributeto substrate specificity of class A beta-lactamase SME-1.Antimicrob. Agents Chemother., 2005, 49, 3421-3427.
198. Cantu, C., 3rd; Huang, W.; Palzkill, T. Cephalosporin substratespecificity determinants of TEM-1 beta-lactamase. J. Biol. Chem.,1997, 272, 29144-29150.
199. Palzkill, T.; Botstein, D. Identification of amino acid substitutionsthat alter the substrate specificity of TEM-1 beta-lactamase. J.Bacteriol., 1992, 174, 5237-5243.
200. Jacoby, G.A.; Bush, K. beta-lactamase nomenclature. J. Clin.Microbiol., 2006, 43, 6220.
201. Huang, W.; Petrosino, J.; Hirsch, M.; Shenkin, P.S.; Palzkill, T. Amino acid sequence determinants of beta-lactamase structure andactivity. J. Mol. Biol., 1996, 258, 688-703.
202. Strynadka, N.C.; Adachi, H.; Jensen, S.E.; Johns, K.; Sielecki, A.; Betzel, C.; Sutoh, K.; James, M.N. Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution.Nature, 1992, 359, 700-705.
203. Thomas, V.L.; McReynolds, A.C.; Shoichet, B.K. Structural basesfor stability-function tradeoffs in antibiotic resistance. J. Mol. Biol.,2010, 396, 47-59.
204. Mammeri, H.; Nazic, H.; Naas, T.; Poirel, L.; Leotard, S.; Nordmann, P. AmpC beta-lactamase in an Escherichia coli clinicalisolate confers resistance to expanded-spectrum cephalosporins. Antimicrob. Agents Chemother., 2004, 48, 4050-4053.
205. Powers, R.A.; Caselli, E.; Focia, P.J.; Prati, F.; Shoichet, B.K.Structures of ceftazidime and its transition-state analogue incomplex with AmpC beta-lactamase: implications for resistancemutations and inhibitor design. Biochemistry, 2001, 40, 9207-9214.
206. Mammeri, H.; Poirel, L.; Fortineau, N.; Nordmann, P. Naturallyoccurring extended-spectrum cephalosporinases in Escherichia coli.Antimicrob. Agents Chemother., 2006, 50, 2573-2576.
207. Mammeri, H.; Poirel, L.; Nordmann, P. Extension of the hydrolysisspectrum of AmpC beta-lactamase of Escherichia coli due to aminoacid insertion in the H-10 helix. J. Antimicrob. Chemother., 2007,60, 490-494.
208. Barnaud, G.; Labia, R.; Raskine, L.; Sanson-Le Pors, M.J.; Philippon, A.; Arlet, G. Extension of resistance to cefepime andcefpirome associated to a six amino acid deletion in the H-10 helixof the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett., 2001, 195, 185-190.
209. Woodford, N.; Livermore, D.M. Infections caused by Gram-positive bacteria: a review of the global challenge. J. Infect., 2009,59(Suppl. 1), S4-16.
210. Stein, R.A.; Goetz, R.M.; Ganea, G.M. Ceftobiprole: a new beta-lactam antibiotic. Int. J. Clin. Pract., 2009, 63, 930-943.
211. Davies, T.A.; Page, M.G.; Shang, W.; Andrew, T.; Kania, M.; Bush, K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa,Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother., 2007, 51, 2621-2624.
212. Noel, G.J. Clinical profile of ceftobiprole, a novel beta-lactamantibiotic. Clin. Microbiol. Infect., 2007, 13(Suppl. 2), 25-29.
213. Queenan, A.M.; Shang, W.; Kania, M.; Page, M.G.; Bush, K. Interactions of ceftobiprole with beta-lactamases from molecularclasses A to D. Antimicrob. Agents Chemother., 2007, 51, 3089-3095.
214. McGee, L.; Biek, D.; Ge, Y.; Klugman, M.; du Plessis, M.; Smith, A. M.; Beall, B.; Whitney, C.G.; Klugman, K.P. In vitro evaluationof the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. AgentsChemother., 2009, 53, 552-556.
215. Talbot, G.H.; Thye, D.; Das, A.; Ge, Y. Phase 2 study ofceftaroline vs standard therapy in treatment of complicated skin andskin structure infections. Antimicrob. Agents Chemother., 2007, 51,3612-3616.
216. Parish, D.; Scheinfeld, N. Ceftaroline fosamil, a cephalosporinderivative for the potential treatment of MRSA infection. Curr.Opin. Investig. Drugs, 2008, 9, 201-209.
217. Moisan, H.; Pruneau, M.; Malouin, F. Binding of ceftaroline topenicillin-binding proteins of Staphylococcus aureus andStreptococcus pneumoniae. J. Antimicrob. Chemother., 2010, 65,713-716.
218. Kosowska-Shick, K.; McGhee, P.L.; Appelbaum, P.C. Affinity ofceftaroline and other beta-lactams for penicillin-binding proteinsfrom Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother., 2010, 54, 1670-1677.
219. Nordmann, P.; Guibert, M. Extended-spectrum beta-lactamases inPseudomonas aeruginosa. J. Antimicrob. Chemother., 1998, 42,128-131.
220. De Champs, C.; Poirel, L.; Bonnet, R.; Sirot, D.; Chanal, C.; Sirot, J.; Nordmann, P. Prospective survey of beta-lactamases producedby ceftazidime- resistant Pseudomonas aeruginosa isolated in aFrench hospital in 2000. Antimicrob. Agents Chemother., 2002, 46,3031-3034.
221. Takeda, S.; Nakai, T.; Wakai, Y.; Ikeda, F.; Hatano, K. In vitro andin vivo activities of a new cephalosporin, FR264205, againstPseudomonas aeruginosa. Antimicrob. Agents Chemother., 2007,51, 826-830.
222. Theuretzbacher, U. Future antibiotics scenarios: is the tide startingto turn? Int. J. Antimicrob. Agents, 2009, 34, 15-20.
223. Juan, C.; Zamorano, L.; Perez, J.L.; Ge, Y.; Oliver, A. Activity of anew antipseudomonal cephalosporin, CXA-101 (FR264205),against carbapenem-resistant and multidrug-resistant Pseudomonasaeruginosa clinical strains. Antimicrob. Agents Chemother., 2010,54, 846-851.
224. Livermore, D.M. Has the era of untreatable infections arrived? J.Antimicrob. Chemother., 2009, 64(Suppl. 1), i29-36.
225. Livermore, D. M. The need for new antibiotics. Clin. Microbiol.Infect., 2004, 10(Suppl. 4), 1-9.
226. Projan, S.J.; Shlaes, D.M. Antibacterial drug discovery: is it alldownhill from here? Clin. Microbiol. Infect., 2004, 10(Suppl. 4),18-22.
227. Vidaillac, C.; Rybak, M.J. Ceftobiprole: first cephalosporin withactivity against methicillin-resistant Staphylococcus aureus. Pharmacotherapy, 2009, 29, 511-525.
228. Livermore, D.M. Can beta-lactams be re-engineered to beatMRSA? Clin. Microbiol. Infect., 2006, 12(Suppl. 2), 11-16.
229. Orencia, M.C.; Yoon, J.S.; Ness, J.E.; Stemmer, W.P.; Stevens, R. C. Predicting the emergence of antibiotic resistance by directedevolution and structural analysis. Nat. Struct. Biol., 2001, 8, 238-242.
230. Volker, C.; Brown, J.R. Bioinformatics and the discovery of novelanti-microbial targets. Curr. Drug Targets Infect. Disord., 2002, 2,279-290.
231. Chan, P.F.; Macarron, R.; Payne, D.J.; Zalacain, M.; Holmes, D. J. Novel antibacterials: a genomics approach to drug discovery. Curr.Drug Targets Infect. Disord., 2002, 2, 291-308.
232. Lupas, A. N. The long coming of computational structural biology. J. Struct. Biol., 2008, 163, 254-257.
233. Hillisch, A.; Pineda, L.F.; Hilgenfeld, R. Utility of homologymodels in the drug discovery process. Drug Discov. Today, 2004,9, 659-669.
234. Barker, J.J. Antibacterial drug discovery and structure-baseddesign. Drug Discov. Today, 2006, 11, 391-404.
235. Alonso, H.; Bliznyuk, A.A.; Gready, J.E. Combining docking andmolecular dynamic simulations in drug design. Med. Res. Rev.,2006, 26, 531-568.
236. Beger, R. D. Computational modeling of biologically activemolecules using NMR spectra. Drug Discov. Today, 2006, 11, 429-435.
237. Miguet, L.; Zervosen, A.; Gerards, T.; Pasha, F.A.; Luxen, A.; Disteche-Nguyen, M.; Thomas, A. Discovery of new inhibitors ofresistant Streptococcus pneumoniae penicillin binding protein(PBP) 2x by structure-based virtual screening. J. Med. Chem.,2009, 52, 5926-5936.
238. Schleifer, K.H.; Kandler, O. Peptidoglycan types of bacterial cellwalls and their taxonomic implications. Bacteriol. Rev., 1972, 36,407-477.
239. Curtis, N.A.; Orr, D.; Ross, G.W.; Boulton, M.G. Affinities ofpenicillins and cephalosporins for the penicillin-binding proteins ofEscherichia coli K-12 and their antibacterial activity. Antimicrob.Agents Chemother., 1979, 16, 533-539.
240. Beadle, B.M.; Shoichet, B.K. Structural bases of stability-functiontradeoffs in enzymes. J. Mol. Biol., 2002, 321, 285-296.
241. Dancer, S.J. The problem with cephalosporins. J. Antimicrob.Chemother., 2001, 48, 463-478.
242. Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y. H.; Bergles, D.E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433, 73-77.
243. Secko, D. Antibiotics that protect the brain. CMAJ., 2005, 172,467-468.
244. Beghi, E.; Bendotti, C.; Mennini, T. Merits of a new drug trial forALS? Science, 2005, 308, 632-633.
245. Eisenstein, M. New career possibilities for certain antibiotics? Lab.Anim. (NY), 2005, 34, 10.
246. Mao, J. Glutamate transporter: an unexpected target for someantibiotics. Mol. Pain, 2005, 1, 5.
247. Miller, T.M.; Cleveland, D.W. Medicine. Treatingneurodegenerative diseases with antibiotics. Science, 2005, 307,361-362.
248. Sung, M.T.; Lai, Y.T.; Huang, C.Y.; Chou, L.Y.; Shih, H.W.; Cheng, W.C.; Wong, C.H.; Ma, C. Crystal structure of themembrane-bound bifunctional transglycosylase PBP1b fromEscherichia coli. Proc. Natl. Acad. Sci. USA, 2009, 106, 8824-8829.
249. Nicola, G.; Fedarovich, A.; Nicholas, R.A.; Davies, C. A largedisplacement of the SXN motif of Cys115-modified penicillin-binding protein 5 from Escherichia coli. Biochem. J., 2005, 392,55-63.
250. Kawai, F.; Clarke, T.B.; Roper, D.I.; Han, G.J.; Hwang, K.Y.; Unzai, S.; Obayashi, E.; Park, S.Y.; Tame, J.R. Crystal Structures of Penicillin-Binding Proteins 4 and 5 from Haemophilusinfluenzae. J. Mol. Biol., 396, 634-645.
251. Powell, A.J.; Tomberg, J.; Deacon, A.M.; Nicholas, R.A.; Davies, C. Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal anunexpectedly subtle mechanism for antibiotic resistance. J. Biol.Chem., 2009, 284, 1202-1212.
252. Yamada, M.; Watanabe, T.; Baba, N.; Takeuchi, Y.; Ohsawa, F.; Gomi, S. Crystal structures of biapenem and tebipenem complexedwith penicillin-binding proteins 2X and 1A from Streptococcuspneumoniae. Antimicrob. Agents Chemother., 2008, 52, 2053-2060.
253. Job, V.; Carapito, R.; Vernet, T.; Dessen, A.; Zapun, A. Commonalterations in PBP1a from resistant Streptococcus pneumoniaedecrease its reactivity toward beta-lactams: structural insights. J.Biol. Chem., 2008, 283, 4886-4894.
254. Macheboeuf, P.; Lemaire, D.; Teller, N.; Martins Ados, S.; Luxen, A.; Dideberg, O.; Jamin, M.; Dessen, A. Trapping of an acyl-enzyme intermediate in a penicillin-binding protein (PBP)-catalyzed reaction. J. Mol. Biol., 2008, 376, 405-413.
255. Macheboeuf, P.; Fischer, D.S.; Brown, T., Jr.; Zervosen, A.; Luxen, A.; Joris, B.; Dessen, A.; Schofield, C.J. Structural and mechanistic basis of penicillin-binding protein inhibition bylactivicins. Nat. Chem. Biol., 2007, 3, 565-569.
256. Lovering, A.L.; De Castro, L.; Lim, D.; Strynadka, N.C. Structuralanalysis of an open form of PBP1B from Strep tococcus pneumoniae. Protein Sci., 2006, 15, 1701-1709.
257. Macheboeuf, P.; Di Guilmi, A.M.; Job, V.; Vernet, T.; Dideberg, O.; Dessen, A., Active site restructuring regulates ligandrecognition in class A penicillin-binding proteins. Proc. Natl. Acad.Sci. USA, 2005, 102, 577-582.
258. Yamada, M.; Watanabe, T.; Miyara, T.; Baba, N.; Saito, J.; Takeuchi, Y.; Ohsawa, F. Crystal structure of cefditoren complexedwith Streptococcus pneumoniae penicillin-binding protein 2X:structural basis for its high antimicrobial activity. Antimicrob. Agents Chemother., 2007, 51, 3902-3907.
259. Pernot, L.; Chesnel, L.; Le Gouellec, A.; Croize, J.; Vernet, T.; Dideberg, O.; Dessen, A. A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism forreduction of susceptibility to beta-lactam antibiotics. J. Biol. Chem., 2004, 279, 16463-16470.
260. Chesnel, L.; Pernot, L.; Lemaire, D.; Champelovier, D.; Croize, J.; Dideberg, O.; Vernet, T.; Zapun, A. The structural modificationsinduced by the M339F substitution in PBP2x from Streptococcuspneumoniae further decreases the susceptibility to beta-lactams ofresistant strains. J. Biol. Chem., 2003, 278, 44448-44456.
261. Lovering, A.L.; de Castro, L.H.; Lim, D.; Strynadka, N. C.Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science, 2007, 315, 1402-1405.
262. Herzberg, O. Refined crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.0 A resolution. J. Mol. Biol., 1991,217, 701-719.
263. Minasov, G.; Wang, X.; Shoichet, B.K. An ultrahigh resolutionstructure of TEM-1 beta-lactamase suggests a role for Glu166 asthe general base in acylation. J. Am. Chem. Soc., 2002, 124, 5333-5340.
264. Wang, X.; Minasov, G.; Shoichet, B. K. The structural bases ofantibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34. J. Biol. Chem., 2002,277, 32149-32156.
265. Wang, X.; Minasov, G.; Shoichet, B. K. Evolution of an antibioticresistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol., 2002, 320, 85-95.
266. Thomas, V.L.; Golemi-Kotra, D.; Kim, C.; Vakulenko, S.B.; Mobashery, S.; Shoichet, B.K. Structural consequences of theinhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry, 2005, 44, 9330-9338.
267. Kuzin, A.P.; Nukaga, M.; Nukaga, Y.; Hujer, A.M.; Bonomo, R.A.; Knox, J.R. Structure of the SHV-1 beta-lactamase. Biochemistry,1999, 38, 5720-5727.
268. Nukaga, M.; Mayama, K.; Hujer, A.M.; Bonomo, R.A.; Knox, J. R.Ultrahigh resolution structure of a class A beta-lactamase: on themechanism and specificity of the extended-spectrum SHV-2enzyme. J. Mol. Biol., 2003, 328, 289-301.
269. Tranier, S.; Bouthors, A.T.; Maveyraud, L.; Guillet, V.; Sougakoff, W.; Samama, J.P. The high resolution crystal structure for class Abeta-lactamase PER-1 reveals the bases for its increase in breadthof activity. J. Biol. Chem., 2000, 275, 28075-28082.
270. Chen, Y.; Bonnet, R.; Shoichet, B.K. The acylation mechanism ofCTX-M beta-lactamase at 0.88 A resolution. J. Am. Chem. Soc.,2007, 129, 5378-5380.
271. Chen, Y.; Shoichet, B.; Bonnet, R. Structure, function, andinhibition along the reaction coordinate of CTX-M beta-lactamases.J. Am. Chem. Soc., 2005, 127, 5423-5434.
272. Chen, Y.; Delmas, J.; Sirot, J.; Shoichet, B.; Bonnet, R. Atomicresolution structures of CTX-M beta-lactamases: extendedspectrum activities from increased mobility and decreased stability.J. Mol. Biol., 2005, 348, 349-362.
273. Ibuka, A.S.; Ishii, Y.; Galleni, M.; Ishiguro, M.; Yamaguchi, K.; Frere, J.M.; Matsuzawa, H.; Sakai, H. Crystal structure ofextended-spectrum beta-lactamase Toho-1: insights into themolecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry, 2003, 42, 10634-10643.
274. Lim, D.; Sanschagrin, F.; Passmore, L.; De Castro, L.; Levesque, R. C.; Strynadka, N.C. Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies. Biochemistry, 2001, 40, 395-402.
275. Fonze, E.; Vanhove, M.; Dive, G.; Sauvage, E.; Frere, J. M.; Charlier, P. Crystal structures of the Bacillus licheniformis BS3class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin. Biochemistry, 2002, 41, 1877-1885.
276. Ke, W.; Bethel, C.R.; Thomson, J.M.; Bonomo, R.A.; van den Akker, F. Crystal structure of KPC-2: insights into carbapenemaseactivity in class A beta-lactamases. Biochemistry, 2007, 46, 5732-5740.
277. Sougakoff, W.; L'Hermite, G.; Pernot, L.; Naas, T.; Guillet, V.; Nordmann, P.; Jarlier, V.; Delettre, J. Structure of the imipenem-hydrolyzing class A beta-lactamase SME-1 from Serratiamarcescens. Acta Crystallogr. D Biol. Crystallogr., 2002, 58, 267-274.
278. Swaren, P.; Maveyraud, L.; Raquet, X.; Cabantous, S.; Duez, C.; Pedelacq, J.D.; Mariotte-Boyer, S.; Mourey, L.; Labia, R.; Nicolas-Chanoine, M.H.; Nordmann, P.; Frere, J.M.; Samama, J.P. X-rayanalysis of the NMC-A beta-lactamase at 1.64-A resolution, a classA carbapenemase with broad substrate specificity. J. Biol. Chem.,1998, 273, 26714-26721.
279. Smith, C.A.; Caccamo, M.; Kantardjieff, K.A.; Vakulenko, S.Structure of GES-1 at atomic resolution: insights into the evolutionof carbapenamase activity in the class A extended-spectrum beta-lactamases. Acta Crystallogr. D Biol. Crystallogr., 2007, 63, 982-992.
280. Davies, A.M.; Rasia, R.M.; Vila, A.J.; Sutton, B.J.; Fabiane, S. M. Effect of pH on the active site of an Arg121Cys mutant of themetallo-beta-lactamase from Bacillus cereus: implications for theenzyme mechanism. Biochemistry, 2005, 44, 4841-4849.
281. Carfi, A.; Duee, E.; Paul-Soto, R.; Galleni, M.; Frere, J. M.; Dideberg, O. X-ray structure of the ZnII beta-lactamase fromBacteroides fragilis in an orthorhombic crystal form. Acta Crystallogr. D Biol. Crystallogr., 1998, 54, 45-57.
282. Kurosaki, H.; Yamaguchi, Y.; Higashi, T.; Soga, K.; Matsueda, S.; Yumoto, H.; Misumi, S.; Yamagata, Y.; Arakawa, Y.; Goto, M. Irreversible inhibition of metallo-beta-lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)propionic acid pentafluorophenyl ester.A ngew. Chem. Int. Ed. Engl., 2005, 44, 3861-3864.
283. Murphy, T.A.; Catto, L.E.; Halford, S.E.; Hadfield, A.T.; Minor, W.; Walsh, T.R.; Spencer, J. Crystal structure of Pseudomonasaeruginosa SPM-1 provides insights into variable zinc affinity ofmetallo-beta-lactamases. J. Mol. Biol., 2006, 357, 890-903.
284. Yamaguchi, Y.; Jin, W.; Matsunaga, K.; Ikemizu, S.; Yamagata, Y.; Wachino, J.; Shibata, N.; Arakawa, Y.; Kurosaki, H. Crystallographic investigation of the inhibition mode of a VIM-2metallo-beta-lactamase from Pseudomonas aeruginosa by amercaptocarboxylate inhibitor. J. Med. Chem., 2007, 50, 6647-6653.
285. Bebrone, C.; Delbruck, H.; Kupper, M.B.; Schlomer, P.; Willmann, C.; Frere, J.M.; Fischer, R.; Galleni, M.; Hoffmann, K.M. Thestructure of the dizinc subclass B2 metallo-beta-lactamase CphAreveals that the second inhibitory zinc ion binds in the histidinesite. Antimicrob. Agents Chemother., 2009, 53, 4464-4471.
286. Stoczko, M.; Frere, J.M.; Rossolini, G.M.; Docquier, J. D. Postgenomic scan of metallo-beta-lactamase homologues inrhizobacteria: identification and characterization of BJP-1, asubclass B3 ortholog from Bradyrhizobium japonicum. Antimicrob.Agents Chemother., 2006, 50, 1973-1981.
287. Garcia-Saez, I.; Mercuri, P.S.; Papamicael, C.; Kahn, R.; Frere, J. M.; Galleni, M.; Rossolini, G.M.; Dideberg, O. Three-dimensional structure of FEZ-1, a monomeric subclass B3 metallo-beta-lactamase from Fluoribacter gormanii, in native form and incomplex with D-captopril. J. Mol. Biol., 2003, 325, 651-660.
288. Ullah, J.H.; Walsh, T.R.; Taylor, I.A.; Emery, D.C.; Verma, C. S.; Gamblin, S.J.; Spencer, J. The crystal structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia at 1.7 Aresolution. J. Mol. Biol., 1998, 284, 125-136.
289. Teotico, D.G.; Babaoglu, K.; Rocklin, G.J.; Ferreira, R. S.; Giannetti, A.M.; Shoichet, B.K. Docking for fragment inhibitors of AmpC beta-lactamase. Proc. Natl. Acad. Sci. USA, 2009, 106,7455-7460.
290. Shimizu-Ibuka, A.; Bauvois, C.; Sakai, H.; Galleni, M. Structure ofthe plasmid-mediated class C beta-lactamase ACT-1. ActaCrystallogr. Sect. F Struct. Biol. Cryst. Commun., 2008, 64, 334-337.
291. Kim, J.Y.; Jung, H.I.; An, Y.J.; Lee, J.H.; Kim, S.J.; Jeong, S. H.; Lee, K.J.; Suh, P.G.; Lee, H.S.; Lee, S.H.; Cha, S.S. Structuralbasis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase. Mol. Microbiol., 2006, 60, 907-916.
292. Nukaga, M.; Kumar, S.; Nukaga, K.; Pratt, R.F.; Knox, J. R. Hydrolysis of third-generation cephalosporins by class C beta-lactamases. Structures of a transition state analog of cefotoxaminein wild-type and extended spectrum enzymes. J. Biol. Chem., 2004,279, 9344-9352.
293. Pernot, L.; Frenois, F.; Rybkine, T.; L'Hermite, G.; Petrella, S.; Delettre, J.; Jarlier, V.; Collatz, E.; Sougakoff, W. Crystalstructures of the class D beta-lactamase OXA-13 in the native formand in complex with meropenem. J. Mol. Biol., 2001, 310, 859-874.
294. Santillana, E.; Beceiro, A.; Bou, G.; Romero, A. Crystal structureof the carbapenemase OXA-24 reveals insights into the mechanismof carbapenem hydrolysis. Proc. Natl. Acad. Sci. USA, 2007, 104,5354-5359.
295. Docquier, J.D.; Benvenuti, M.; Calderone, V.; Giuliani, F.; Kapetis, D.; De Luca, F.; Rossolini, G.M.; Mangani, S. Crystal structure ofthe narrow-spectrum OXA-46 class D beta-lactamase: relationshipbetween active-site lysine carbamylation and inhibition bypolycarboxylates. Antimicrob. Agents Chemother., 2010, 54, 2167-2174.